Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome

A. Mezheyeuski, U. Segersten, LW. Leiss, PU. Malmström, J. Hatina, A. Östman, C. Strell,

. 2020 ; 10 (1) : 281. [pub] 20200114

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028605

Little attention was given to the interaction between tumor and stromal cells in urothelial bladder carcinoma (UBC). While recent studies point towards the existence of different fibroblast subsets, no comprehensive analyses linking different fibroblast markers to UBC patient survival have been performed so far. Through immunohistochemical analysis of five selected fibroblast markers, namely alpha smooth muscle actin (ASMA), CD90/Thy-1, fibroblast activation protein (FAP), platelet derived growth factor receptor-alpha and -beta (PDGFRa,-b), this study investigates their association with survival and histopathological characteristics in a cohort of 344 UBC patients, involving both, muscle-invasive and non-muscle-invasive cases. The data indicates that combinations of stromal markers are more suited to identify prognostic patient subgroups than single marker analysis. Refined stroma-marker-based patient stratification was achieved through cluster analysis and identified a FAP-dominant patient cluster as independent marker for shorter 5-year-survival (HR(95% CI)2.25(1.08-4.67), p = 0.030). Analyses of interactions between fibroblast and CD8a-status identified a potential minority of cases with CD90-defined stroma and high CD8a infiltration showing a good prognosis of more than 80% 5-year-survival. Presented analyses point towards the existence of different stroma-cell subgroups with distinct tumor-modulatory properties and motivate further studies aiming to better understand the molecular tumor-stroma crosstalk in UBC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028605
003      
CZ-PrNML
005      
20210114154423.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-019-55013-0 $2 doi
035    __
$a (PubMed)31937798
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Mezheyeuski, Artur $u Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
245    10
$a Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome / $c A. Mezheyeuski, U. Segersten, LW. Leiss, PU. Malmström, J. Hatina, A. Östman, C. Strell,
520    9_
$a Little attention was given to the interaction between tumor and stromal cells in urothelial bladder carcinoma (UBC). While recent studies point towards the existence of different fibroblast subsets, no comprehensive analyses linking different fibroblast markers to UBC patient survival have been performed so far. Through immunohistochemical analysis of five selected fibroblast markers, namely alpha smooth muscle actin (ASMA), CD90/Thy-1, fibroblast activation protein (FAP), platelet derived growth factor receptor-alpha and -beta (PDGFRa,-b), this study investigates their association with survival and histopathological characteristics in a cohort of 344 UBC patients, involving both, muscle-invasive and non-muscle-invasive cases. The data indicates that combinations of stromal markers are more suited to identify prognostic patient subgroups than single marker analysis. Refined stroma-marker-based patient stratification was achieved through cluster analysis and identified a FAP-dominant patient cluster as independent marker for shorter 5-year-survival (HR(95% CI)2.25(1.08-4.67), p = 0.030). Analyses of interactions between fibroblast and CD8a-status identified a potential minority of cases with CD90-defined stroma and high CD8a infiltration showing a good prognosis of more than 80% 5-year-survival. Presented analyses point towards the existence of different stroma-cell subgroups with distinct tumor-modulatory properties and motivate further studies aiming to better understand the molecular tumor-stroma crosstalk in UBC.
650    _2
$a aktiny $x metabolismus $7 D000199
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a CD8-pozitivní T-lymfocyty $x cytologie $x imunologie $x metabolismus $7 D018414
650    _2
$a shluková analýza $7 D016000
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblasty $x cytologie $x metabolismus $7 D005347
650    _2
$a želatinasy $x metabolismus $7 D018093
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránové proteiny $x metabolismus $7 D008565
650    _2
$a fenotyp $7 D010641
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a růstový faktor odvozený z trombocytů - receptor alfa $x metabolismus $7 D020796
650    _2
$a serinové endopeptidasy $x metabolismus $7 D012697
650    _2
$a antigeny Thy-1 $x metabolismus $7 D018800
650    _2
$a nádory močového měchýře $x metabolismus $x mortalita $x patologie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Segersten, Ulrika $u Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
700    1_
$a Leiss, Lina Wik $u Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Malmström, Per-Uno $u Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
700    1_
$a Hatina, Jiri $u Charles University, Faculty of Medicine in Pilsen, Institut of Biology, Plzen, Czech Republic.
700    1_
$a Östman, Arne $u Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Strell, Carina $u Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. carina.strell@igp.uu.se. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. carina.strell@igp.uu.se.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 281
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31937798 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154420 $b ABA008
999    __
$a ok $b bmc $g 1608940 $s 1119785
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 1 $d 281 $e 20200114 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace